Celcuity hits record high on breast cancer drug trial data

Shares of drug developer Celcuity CELC.O surge 197% to all-time high of $40.93

Stock set for its best day on record, if gains hold

Co says its experimental drug, gedatolisib, combined with Pfizer's PFE.N Ibrance and AstraZeneca's AZN.L Faslodex, delayed advanced breast cancer progression by more than seven months, compared to Faslodex alone in a late-stage study

The triple combo drug cut the risk of disease progression or death by 76%, compared to Faslodex in previously treated HR+/HER2- advanced breast cancer patients, co says

*The study showed "unprecedented results", Leerink Partners analyst Andrew Berens says, adding that gedatolisib could become a new standard of care as a second-line treatment in breast cancer, especially in the community settings

Triple combo patients lived 9.3 months without progression versus two months with Faslodex alone, co adds

CELC says the treatment was better tolerated than in previous early-stage studies, with lower rates of high blood sugar and mouth inflammation

CELC says it plans to apply for U.S. marketing approval in Q4 2025

As of last close, stock up 5.2% YTD